Dr. Gross joined HMRI and the Molecular Neurology Program in 2014. The focus of Noah’s work is on determining the neurobiological mechanisms underlying migraine, in humans, and animal models of migraine.
Dr. Gross received his BS in Psychobiology from UCLA in 2001, and his PhD in Neuroscience from UCI in 2010. His research interests at UCI included the neuroscientific study of neurodegenerative disorders, and drug addiction/neurotoxicity. His initial accomplishments at UCI involved assessing the therapeutic role of exercise in a rodent model of Parkinson’s disease, and in his dissertation, Noah investigated the rodent neural circuitry implicated in methamphetamine-induced neurotoxicity. For his thesis work, Noah developed novel surgical and in vivo drug administration procedures to perform simultaneous brain infusion and subcutaneous drug administration in freely-moving animals. For his postdoctoral studies, Noah extended his research interests in molecular neuroscience by validating a novel transgenic animal capable of enhanced neuronal transduction by viral-vector delivery. To this end, Noah delivered adenoviral vectors into major brain pathways to retrogradely identify neural circuits, and subsequently, to manipulate specific neuronal populations following intracerebral infusion of ShRNA- and optogenetic-based viral vectors.
Dr. Gross intends to utilize his knowledge of rodent surgical techniques to further investigate the seminal findings of the Molecular Neurology Program in which Dr. Harrington’s lab was the first to discover that sodium and the sodium-potassium pump are key players in migraine pathophysiology. The goal of Noah’s research will be to elucidate the neurobiological mechanisms underlying sodium-related dysregulation of the sodium-potassium pump in an effort to derive safe and efficacious treatments for people suffering from migraine.